Effects of female sex hormones and contraceptive pill on the diagnostic work-up for primary aldosteronism

Journal of Hypertension

Volumn 28, Issue 1, 2010, Pages 135-142

  Pizzolo, Francesca ^a   Raffaelli, Ricciarda ^b   Memmo, Alessia ^b   Chiecchi, Laura ^a   Pavan, Chiara ^a   Guarini, Patrizia ^a   Guidi, Gian Cesare ^a   Franchi, Massimo ^a   Corrocher, Roberto ^a   Olivieri, Oliviero ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Section of Gynaecology and Obstetrics ^*  (Italy)

Author keywords

Diagnosis; Female hormones; Primary aldosteronism

Indexed keywords

ALDOSTERONE; ORAL CONTRACEPTIVE AGENT; RENIN; SEX HORMONE;

ADULT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; FEMALE; FOLLICULAR PHASE; HUMAN; HYPERTENSION; LUTEAL PHASE; MAJOR CLINICAL STUDY; MALE; MENSTRUAL CYCLE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SALT LOADING; SCREENING;

EID: 73849087180     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833266e3     Document Type: Article

References (39)

1. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21:315-318.
2. Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85:1863-1867.
3. Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42:161-165.
4. Young WF. Minireview: primary aldosteronism-changing concepts in diagnosis and treatment. Endocrinology 2003; 114:2208-2213.
5. Mulatero P,Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89:1045-1050.
6. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol 2006; 48:2293-2300.
7. Mulatero P, Dluhy RG, Giacchetti G, Boscaro M, Veglio F, Stewart PM. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metab 2005; 16:114-119.
8. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3266-3281.
9. Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, et al. Screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 1981; 141:1589-1593.
10. Sealey JE, Gordon RD, Mantero F. Plasma renin and aldosterone measurements in low renin hypertensive states. Trends Endocrinol Metab 2005; 16:86-91; Review.
11. Pizzolo F, Corgnati A, Guarini P, Pavan C, Bassi A, Corrocher R, Olivieri O. Plasma aldosterone assays: comparison between chemiluminescence-based and RIA methods. Clin Chem 2006; 52:1431-1432.
12. Stowasser M, Gordon RD. Aldosterone assays: an urgent need for improvement. Clin Chem 2006; 52:1640-1642.
13. Schirpenbach C, Seiler L, Maser-Gluth C, Beuschlein F, Reincke M, Bidlingmaier M. Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps. Clin Chem 2006; 52:1749-1755.
14. Tanabe A, Naruse M, Takagi S, Tsuchiya K, Imaki T, Takano K. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab 2003; 88:2489-2494.
15. Schwartz GL, Chapman AB, Boerwinkle E, Kisabeth RM, Turner ST. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem 2002; 48:1919-1923.
16. Montori VM, Young WF Jr. Use of plasma aldosterone concentration-to- plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am 2002; 31:619-632; Review.
17. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 2005; 51:386-394.
18. Mulatero P, Milan A, Fallo F, Regolisti G, Pizzolo F, Fardella C, et al. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab 2006; 91:2618-2623.
19. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37:699-705.
20. Olivieri O, Ciacciarelli A, Signorelli D, Pizzolo F, Guarini P, Pavan C, et al. Aldosterone to renin ratio in a primary care setting: the Bussolengo study. J Clin Endocrinol Metab 2004; 89:4221-4226.
21. Newton-Cheh C, Guo CY, Gona P, Larson MG, Benjamin EJ, Wang TJ, et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2007; 49:846-856.
22. Stowasser M, Bachmann AW, Huggard PJ, Rossetti TR, Gordon RD. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and to degree of biochemical disturbance. J Clin Endocrinol Metab 2000; 85:2160-2166.
23. Zarnegar R, Young WF Jr, Lee J, Sweet MP, Kebebew E, Farley DR, et al. The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann Surg 2008; 247:511-518.
24. Olivieri O, Pizzolo F, Ciacciarelli A, Corrocher R, Signorelli D, Falcone S, Blengio GS. Menopause not aldosterone-to-renin ratio predicts blood pressure response to a mineralocorticoid receptor antagonist in primary care hypertensive patients. Am J Hypertens 2008; 21:976-982.
25. Holland OB, Brown H, Kuhnert L, Fairchild C, Risk M, Gomez-Sanchez CE. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension 1984; 6:717-723.
26. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40:897-902.
27. Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab 2008; 19:88-90.
28. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243-1248.
29. Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, Marwick TH. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 2005; 90:5070-5076.
30. Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 2004; 22:863-869.
31. Kaplan NM. Is there an unrecognized epidemic of primary aldosteronism? Con. Hypertension 2007; 50:454-458.
32. Calhoun DA. Is there an unrecognized epidemic of primary aldosteronism? Pro. Hypertension 2007; 50:447-453; Review.
33. Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 1996; 61:166-171; Review.
34. Szmuilowicz ED, Adler GK, Williams JS, Green DE, Yao TM, Hopkins PN, Seely EW. Relationship between aldosterone and progesterone in the human menstrual cycle. J Clin Endocrinol Metab 2006; 91:3981-3987.
35. Fommei E, Ghione S,Ripoli A, Maffei S, Di Cecco P, Iervasi A, Turchi S. The ovarian cycle as a factor of variability in the laboratory screening for primary aldosteronism in women. J Hum Hypertens 2009; 23:130-135.
36. Pizzolo F, Pavan C, Corrocher R, Olivieri O. Laboratory diagnosis of primary aldosteronism, and drospirenone-ethinylestradiol therapy. Am J Hypertens 2007; 20:1334-1337.
37. White WB, Pitt B, Prston RA, Hanes V. Antihypertensive effects of drospirenone with 17-b-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005; 112:1979-1984.
38. White WB, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17-b-estradiol, in postmenopausal women with hypertension. Hypertension 2006; 48:246-253.
39. Sica DA. Drospirenone: an antihypertensive in waiting. Hypertension 2006; 48:205-206.